Amlodipine Label Updates 2020 to 2026: FDA Safety Changes, New Warnings, and What Clinicians Need to Know

Did amlodipine get a new boxed warning or a new contraindication?

No boxed warning appears on the amlodipine label, and the Contraindications section is a single line: known sensitivity to amlodipine [1][2].

The safety content sits in section 5, Warnings and Precautions, which has three subsections [2]:

• Symptomatic hypotension is possible, particularly in severe aortic stenosis; because onset of action is gradual, acute hypotension is unlikely [2].
• Worsening angina and acute myocardial infarction can develop after starting amlodipine or increasing the dose, particularly in severe obstructive coronary artery disease [2].
• The label says to titrate slowly in severe hepatic impairment; it gives a plasma elimination half-life of 56 hours in impaired hepatic function [2].

What the Drugs@FDA record shows for 2020 to 2026

Norvasc tablets of 2.5, 5 and 10 mg are approved under NDA 019787, with an original approval date of July 31, 1992; the company listed on the application is now Viatris [1]. The supplement history on that page includes a September 28, 2005 efficacy supplement for a new indication, the angiographically documented coronary artery disease indication [1]. The newest labeling-package-insert entry in that table is SUPPL-62, dated October 30, 2017, and no entry dated 2020 or later appears there [1].

The dates in that window belong to a different application. Caduet, amlodipine plus atorvastatin (NDA 021540, original approval January 30, 2004), has labeling-package-insert supplements dated September 25, 2020, December 15, 2020, January 7, 2021, May 17, 2024 and November 4, 2024 [3]. Caduet is a fixed-dose combination with its own prescribing information, so those revision dates describe the combination label, not the single-ingredient amlodipine label [3].

The current generic amlodipine besylate tablet prescribing information carries an effective date of April 20, 2026 [2].

What the current label says about dosing

For adults with hypertension, the label gives a starting dose of 5 mg once daily and a maximum of 10 mg once daily. Small, fragile or elderly patients, patients with hepatic insufficiency, and patients adding amlodipine to another antihypertensive may start at 2.5 mg [2]. The label says to wait 7 to 14 days between titration steps, and to titrate faster only if clinically warranted with frequent assessment [2]. For chronic stable or vasospastic angina the labeled dose is 5 to 10 mg, and for coronary artery disease 5 to 10 mg once daily; for both, most patients need 10 mg [2].

Interactions: where the label is most specific

Simvastatin is the interaction with a hard number attached: co-administration raises simvastatin exposure, and the label says not to exceed 20 mg of simvastatin daily in patients taking amlodipine [2].

For CYP3A inhibitors, the label states that moderate and strong inhibitors increase systemic exposure to amlodipine and may require a dose reduction, with monitoring for hypotension and edema [2]. For CYP3A inducers, the label states that no quantitative information is available and that blood pressure should be monitored closely [2]. For sildenafil, the label calls for monitoring for hypotension [2]. Amlodipine may increase exposure to cyclosporine and tacrolimus, and the label recommends frequent trough-level monitoring with dose adjustment when appropriate [2].

A population-based Ontario cohort of adults with a mean age of 76 taking a calcium-channel blocker (amlodipine in more than half) looked at clarithromycin, a CYP3A4 inhibitor, versus azithromycin, which is not. Patients were newly given clarithromycin (n=96,226) or azithromycin (n=94,083). Within 30 days, hospitalization with acute kidney injury occurred in 0.44% versus 0.22% (odds ratio 1.98, 95% CI 1.68 to 2.34), and all-cause mortality in 1.02% versus 0.59% [4].

Pregnancy and lactation sections

On pregnancy, the label states that limited post-marketing data are not sufficient to inform a drug-associated risk of major birth defects or miscarriage, and that poorly controlled hypertension itself carries maternal and fetal risks [2]. In rats given about 10 times the maximum recommended human dose, litter size fell by about 50%, intrauterine deaths rose about 5-fold, and gestation and labor were prolonged; no adverse developmental effects appeared in rats and rabbits during organogenesis at about 10 and 20 times the maximum recommended human dose [2]. On lactation, amlodipine is present in human milk at an estimated median relative infant dose of 4.2%, with no adverse effects observed in breastfed infants and no information on milk production [2].

Pediatric, older adult and hepatic dosing

Children 6 to 17 years with hypertension are labeled at 2.5 to 5 mg once daily; doses above 5 mg have not been studied in pediatric patients, and the effect in children under 6 is not known [2]. In the label's pediatric trial, 268 hypertensive patients aged 6 to 17 were randomized to amlodipine 2.5 or 5 mg once daily for 4 weeks and then re-randomized to the same dose or placebo for another 4 weeks; those on active drug at the end of 8 weeks had significantly lower systolic blood pressure [2]. For older adults the label says to start at the low end of the dose range [2]. For hepatic impairment, the label says patients with hepatic insufficiency may start at 2.5 mg once daily, and that titration should be slow in severe hepatic impairment [2].